Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.

Oncotarget

Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, Wardelmann E, Hartmann W, Rahbar K, Huss S.
PMID: 29515776
Oncotarget. 2018 Jan 04;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 09.

AIM: PSMA (prostate-specific membrane antigen) is physiologically expressed in normal prostate tissue and over expressed in prostate cancer cells, therefore constituting a potential target for antibody-based radioligand therapy. Very recent imaging findings reported PSMA-PET/CT uptake in various thyroid lesions....

Cite
Heitkötter B, Steinestel K, Trautmann M, et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018;9(11):9867-9874doi: 10.18632/oncotarget.23984.
Heitkötter, B., Steinestel, K., Trautmann, M., Grünewald, I., Barth, P., Gevensleben, H., Bögemann, M., Wardelmann, E., Hartmann, W., Rahbar, K., & Huss, S. (2018). Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget, 9(11), 9867-9874. https://doi.org/10.18632/oncotarget.23984
Heitkötter, Birthe, et al. "Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid." Oncotarget vol. 9,11 (2018): 9867-9874. doi: https://doi.org/10.18632/oncotarget.23984
Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, Wardelmann E, Hartmann W, Rahbar K, Huss S. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018 Jan 04;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 09. PMID: 29515776; PMCID: PMC5839407.
Copy Download .nbib Format: NLM
Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects.

Frontiers in human neuroscience

Strehl U, Aggensteiner P, Wachtlin D, Brandeis D, Albrecht B, Arana M, Bach C, Banaschewski T, Bogen T, Flaig-Röhr A, Freitag CM, Fuchsenberger Y, Gest S, Gevensleben H, Herde L, Hohmann S, Legenbauer T, Marx AM, Millenet S, Pniewski B, Rothenberger A, Ruckes C, Wörz S, Holtmann M.
PMID: 28408873
Front Hum Neurosci. 2017 Mar 31;11:135. doi: 10.3389/fnhum.2017.00135. eCollection 2017.

No abstract available.

Cite
Strehl U, Aggensteiner P, Wachtlin D, et al. Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects. Front Hum Neurosci. 2017;11:135doi: 10.3389/fnhum.2017.00135.
Strehl, U., Aggensteiner, P., Wachtlin, D., Brandeis, D., Albrecht, B., Arana, M., Bach, C., Banaschewski, T., Bogen, T., Flaig-Röhr, A., Freitag, C. M., Fuchsenberger, Y., Gest, S., Gevensleben, H., Herde, L., Hohmann, S., Legenbauer, T., Marx, A. M., Millenet, S., Pniewski, B., Rothenberger, A., Ruckes, C., Wörz, S., & Holtmann, M. (2017). Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects. Frontiers in human neuroscience, 11135. https://doi.org/10.3389/fnhum.2017.00135
Strehl, Ute, et al. "Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects." Frontiers in human neuroscience vol. 11 (2017): 135. doi: https://doi.org/10.3389/fnhum.2017.00135
Strehl U, Aggensteiner P, Wachtlin D, Brandeis D, Albrecht B, Arana M, Bach C, Banaschewski T, Bogen T, Flaig-Röhr A, Freitag CM, Fuchsenberger Y, Gest S, Gevensleben H, Herde L, Hohmann S, Legenbauer T, Marx AM, Millenet S, Pniewski B, Rothenberger A, Ruckes C, Wörz S, Holtmann M. Neurofeedback of Slow Cortical Potentials in Children with Attention-Deficit/Hyperactivity Disorder: A Multicenter Randomized Trial Controlling for Unspecific Effects. Front Hum Neurosci. 2017 Mar 31;11:135. doi: 10.3389/fnhum.2017.00135. eCollection 2017. PMID: 28408873; PMCID: PMC5374218.
Copy Download .nbib Format: NLM
Pathophysiology of ADHD and associated problems-starting points for NF interventions?.

Frontiers in human neuroscience

Albrecht B, Uebel-von Sandersleben H, Gevensleben H, Rothenberger A.
PMID: 26157377
Front Hum Neurosci. 2015 Jun 24;9:359. doi: 10.3389/fnhum.2015.00359. eCollection 2015.

Attention deficit hyperactivity disorder (ADHD) is characterized by severe and age-inappropriate levels of hyperactivity, impulsivity and inattention. ADHD is a heterogeneous disorder, and the majority of patients show comorbid or associated problems from other psychiatric disorders. Also, ADHD is...

Cite
Albrecht B, Uebel-von Sandersleben H, Gevensleben H, et al. Pathophysiology of ADHD and associated problems-starting points for NF interventions?. Front Hum Neurosci. 2015;9:359doi: 10.3389/fnhum.2015.00359.
Albrecht, B., Uebel-von Sandersleben, H., Gevensleben, H., & Rothenberger, A. (2015). Pathophysiology of ADHD and associated problems-starting points for NF interventions?. Frontiers in human neuroscience, 9359. https://doi.org/10.3389/fnhum.2015.00359
Albrecht, Björn, et al. "Pathophysiology of ADHD and associated problems-starting points for NF interventions?." Frontiers in human neuroscience vol. 9 (2015): 359. doi: https://doi.org/10.3389/fnhum.2015.00359
Albrecht B, Uebel-von Sandersleben H, Gevensleben H, Rothenberger A. Pathophysiology of ADHD and associated problems-starting points for NF interventions?. Front Hum Neurosci. 2015 Jun 24;9:359. doi: 10.3389/fnhum.2015.00359. eCollection 2015. PMID: 26157377; PMCID: PMC4478393.
Copy Download .nbib Format: NLM
[No title available]

Oncoimmunology

Goltz D, Gevensleben H, Dietrich J, Dietrich D.
PMID: 28197377
Oncoimmunology. 2016 Nov 10;6(1):e1257454. doi: 10.1080/2162402X.2016.1257454. eCollection 2017.

This study evaluates promoter methylation of the programmed cell death ligand 1 (PD-L1) as a biomarker in a cohort of 383 colorectal cancer patients.

Cite
Goltz D, Gevensleben H, Dietrich J, et al. . Oncoimmunology. 2016;6(1):e1257454doi: 10.1080/2162402X.2016.1257454.
Goltz, D., Gevensleben, H., Dietrich, J., & Dietrich, D. (2017). . Oncoimmunology, 6(1), e1257454. https://doi.org/10.1080/2162402X.2016.1257454
Goltz, Diane, et al. "." Oncoimmunology vol. 6,1 (2017): e1257454. doi: https://doi.org/10.1080/2162402X.2016.1257454
Goltz D, Gevensleben H, Dietrich J, Dietrich D. . Oncoimmunology. 2016 Nov 10;6(1):e1257454. doi: 10.1080/2162402X.2016.1257454. eCollection 2017. PMID: 28197377; PMCID: PMC5283627.
Copy Download .nbib Format: NLM
Neurofeedback in attention-deficit/hyperactivity disorder - different models, different ways of application.

Frontiers in human neuroscience

Gevensleben H, Moll GH, Rothenberger A, Heinrich H.
PMID: 25374528
Front Hum Neurosci. 2014 Oct 21;8:846. doi: 10.3389/fnhum.2014.00846. eCollection 2014.

In children with attention-deficit/hyperactivity disorder (ADHD), different neurofeedback (NF) protocols have been applied, with the most prominent differentiation between EEG frequency-band (e.g., theta/beta) training and training of slow cortical potentials (SCPs). However, beyond distinctions between such basic NF variables,...

Cite
Gevensleben H, Moll GH, Rothenberger A, et al. Neurofeedback in attention-deficit/hyperactivity disorder - different models, different ways of application. Front Hum Neurosci. 2014;8:846doi: 10.3389/fnhum.2014.00846.
Gevensleben, H., Moll, G. H., Rothenberger, A., & Heinrich, H. (2014). Neurofeedback in attention-deficit/hyperactivity disorder - different models, different ways of application. Frontiers in human neuroscience, 8846. https://doi.org/10.3389/fnhum.2014.00846
Gevensleben, Holger, et al. "Neurofeedback in attention-deficit/hyperactivity disorder - different models, different ways of application." Frontiers in human neuroscience vol. 8 (2014): 846. doi: https://doi.org/10.3389/fnhum.2014.00846
Gevensleben H, Moll GH, Rothenberger A, Heinrich H. Neurofeedback in attention-deficit/hyperactivity disorder - different models, different ways of application. Front Hum Neurosci. 2014 Oct 21;8:846. doi: 10.3389/fnhum.2014.00846. eCollection 2014. PMID: 25374528; PMCID: PMC4204462.
Copy Download .nbib Format: NLM
Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability.

Frontiers in human neuroscience

Studer P, Kratz O, Gevensleben H, Rothenberger A, Moll GH, Hautzinger M, Heinrich H.
PMID: 25104932
Front Hum Neurosci. 2014 Jul 24;8:555. doi: 10.3389/fnhum.2014.00555. eCollection 2014.

Neurofeedback (NF) is being successfully applied, among others, in children with attention deficit/hyperactivity disorder (ADHD) and as a peak performance training in healthy subjects. However, the neuronal mechanisms mediating a successful NF training have not yet been sufficiently uncovered...

Cite
Studer P, Kratz O, Gevensleben H, et al. Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability. Front Hum Neurosci. 2014;8:555doi: 10.3389/fnhum.2014.00555.
Studer, P., Kratz, O., Gevensleben, H., Rothenberger, A., Moll, G. H., Hautzinger, M., & Heinrich, H. (2014). Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability. Frontiers in human neuroscience, 8555. https://doi.org/10.3389/fnhum.2014.00555
Studer, Petra, et al. "Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability." Frontiers in human neuroscience vol. 8 (2014): 555. doi: https://doi.org/10.3389/fnhum.2014.00555
Studer P, Kratz O, Gevensleben H, Rothenberger A, Moll GH, Hautzinger M, Heinrich H. Slow cortical potential and theta/beta neurofeedback training in adults: effects on attentional processes and motor system excitability. Front Hum Neurosci. 2014 Jul 24;8:555. doi: 10.3389/fnhum.2014.00555. eCollection 2014. PMID: 25104932; PMCID: PMC4109432.
Copy Download .nbib Format: NLM
Neurofeedback of slow cortical potentials: neural mechanisms and feasibility of a placebo-controlled design in healthy adults.

Frontiers in human neuroscience

Gevensleben H, Albrecht B, Lütcke H, Auer T, Dewiputri WI, Schweizer R, Moll G, Heinrich H, Rothenberger A.
PMID: 25566020
Front Hum Neurosci. 2014 Dec 11;8:990. doi: 10.3389/fnhum.2014.00990. eCollection 2014.

To elucidate basic mechanisms underlying neurofeedback we investigated neural mechanisms of training of slow cortical potentials (SCPs) by considering EEG- and fMRI. Additionally, we analyzed the feasibility of a double-blind, placebo-controlled design in NF research based on regulation performance...

Cite
Gevensleben H, Albrecht B, Lütcke H, et al. Neurofeedback of slow cortical potentials: neural mechanisms and feasibility of a placebo-controlled design in healthy adults. Front Hum Neurosci. 2014;8:990doi: 10.3389/fnhum.2014.00990.
Gevensleben, H., Albrecht, B., Lütcke, H., Auer, T., Dewiputri, W. I., Schweizer, R., Moll, G., Heinrich, H., & Rothenberger, A. (2014). Neurofeedback of slow cortical potentials: neural mechanisms and feasibility of a placebo-controlled design in healthy adults. Frontiers in human neuroscience, 8990. https://doi.org/10.3389/fnhum.2014.00990
Gevensleben, Holger, et al. "Neurofeedback of slow cortical potentials: neural mechanisms and feasibility of a placebo-controlled design in healthy adults." Frontiers in human neuroscience vol. 8 (2014): 990. doi: https://doi.org/10.3389/fnhum.2014.00990
Gevensleben H, Albrecht B, Lütcke H, Auer T, Dewiputri WI, Schweizer R, Moll G, Heinrich H, Rothenberger A. Neurofeedback of slow cortical potentials: neural mechanisms and feasibility of a placebo-controlled design in healthy adults. Front Hum Neurosci. 2014 Dec 11;8:990. doi: 10.3389/fnhum.2014.00990. eCollection 2014. PMID: 25566020; PMCID: PMC4263073.
Copy Download .nbib Format: NLM
Promoter methylation of the immune checkpoint receptor .

Oncoimmunology

Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G, Dietrich D.
PMID: 27853645
Oncoimmunology. 2016 Sep 02;5(10):e1221555. doi: 10.1080/2162402X.2016.1221555. eCollection 2016.

Biomarkers that facilitate the prediction of disease recurrence in prostate cancer (PCa) may enable physicians to personalize treatment for individual patients. In the current study,

Cite
Goltz D, Gevensleben H, Dietrich J, et al. Promoter methylation of the immune checkpoint receptor . Oncoimmunology. 2016;5(10):e1221555doi: 10.1080/2162402X.2016.1221555.
Goltz, D., Gevensleben, H., Dietrich, J., Ellinger, J., Landsberg, J., Kristiansen, G., & Dietrich, D. (2016). Promoter methylation of the immune checkpoint receptor . Oncoimmunology, 5(10), e1221555. https://doi.org/10.1080/2162402X.2016.1221555
Goltz, Diane, et al. "Promoter methylation of the immune checkpoint receptor ." Oncoimmunology vol. 5,10 (2016): e1221555. doi: https://doi.org/10.1080/2162402X.2016.1221555
Goltz D, Gevensleben H, Dietrich J, Ellinger J, Landsberg J, Kristiansen G, Dietrich D. Promoter methylation of the immune checkpoint receptor . Oncoimmunology. 2016 Sep 02;5(10):e1221555. doi: 10.1080/2162402X.2016.1221555. eCollection 2016. PMID: 27853645; PMCID: PMC5087295.
Copy Download .nbib Format: NLM
Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in .

Journal of medical genetics

Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, De Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altmüller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, Nürnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E.
PMID: 33273034
J Med Genet. 2020 Dec 03; doi: 10.1136/jmedgenet-2020-107353. Epub 2020 Dec 03.

Variant-specific loss of heterozygosity (LOH) analyses may be useful to classify

Cite
Hauke J, Harter P, Ernst C, et al. Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in . J Med Genet. 2020;doi: 10.1136/jmedgenet-2020-107353.
Hauke, J., Harter, P., Ernst, C., Burges, A., Schmidt, S., Reuss, A., Borde, J., De Gregorio, N., Dietrich, D., El-Balat, A., Kayali, M., Gevensleben, H., Hilpert, F., Altmüller, J., Heimbach, A., Meier, W., Schoemig-Markiefka, B., Thiele, H., Kimmig, R., Nürnberg, P., Kast, K., Richters, L., Sehouli, J., Schmutzler, R. K., & Hahnen, E. (2020). Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in . Journal of medical genetics, . https://doi.org/10.1136/jmedgenet-2020-107353
Hauke, Jan, et al. "Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in ." Journal of medical genetics vol. (2020). doi: https://doi.org/10.1136/jmedgenet-2020-107353
Hauke J, Harter P, Ernst C, Burges A, Schmidt S, Reuss A, Borde J, De Gregorio N, Dietrich D, El-Balat A, Kayali M, Gevensleben H, Hilpert F, Altmüller J, Heimbach A, Meier W, Schoemig-Markiefka B, Thiele H, Kimmig R, Nürnberg P, Kast K, Richters L, Sehouli J, Schmutzler RK, Hahnen E. Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in . J Med Genet. 2020 Dec 03; doi: 10.1136/jmedgenet-2020-107353. Epub 2020 Dec 03. PMID: 33273034.
Copy Download .nbib Format: NLM
Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination.

Oncoimmunology

Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M, Janssen KP, Nitsche U, Garbi N, Brossart P, Knolle PA, Kurts C, Höchst B.
PMID: 28920004
Oncoimmunology. 2017 Jun 16;6(8):e1338995. doi: 10.1080/2162402X.2017.1338995. eCollection 2017.

Tumor immune escape is a critical problem which frequently accounts for the failure of therapeutic tumor vaccines. Among the most potent suppressors of tumor immunity are myeloid derived suppressor cells (MDSCs). MDSCs can be targeted by all-trans-retinoic-acid (atRA), which...

Cite
Heine A, Flores C, Gevensleben H, et al. Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination. Oncoimmunology. 2017;6(8):e1338995doi: 10.1080/2162402X.2017.1338995.
Heine, A., Flores, C., Gevensleben, H., Diehl, L., Heikenwalder, M., Ringelhan, M., Janssen, K. P., Nitsche, U., Garbi, N., Brossart, P., Knolle, P. A., Kurts, C., & Höchst, B. (2017). Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination. Oncoimmunology, 6(8), e1338995. https://doi.org/10.1080/2162402X.2017.1338995
Heine, Annkristin, et al. "Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination." Oncoimmunology vol. 6,8 (2017): e1338995. doi: https://doi.org/10.1080/2162402X.2017.1338995
Heine A, Flores C, Gevensleben H, Diehl L, Heikenwalder M, Ringelhan M, Janssen KP, Nitsche U, Garbi N, Brossart P, Knolle PA, Kurts C, Höchst B. Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination. Oncoimmunology. 2017 Jun 16;6(8):e1338995. doi: 10.1080/2162402X.2017.1338995. eCollection 2017. PMID: 28920004; PMCID: PMC5593699.
Copy Download .nbib Format: NLM
Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study.

Frontiers in human neuroscience

Marx AM, Ehlis AC, Furdea A, Holtmann M, Banaschewski T, Brandeis D, Rothenberger A, Gevensleben H, Freitag CM, Fuchsenberger Y, Fallgatter AJ, Strehl U.
PMID: 25610390
Front Hum Neurosci. 2015 Jan 07;8:1038. doi: 10.3389/fnhum.2014.01038. eCollection 2014.

In this pilot study near-infrared spectroscopy (NIRS) neurofeedback was investigated as a new method for the treatment of Attention Deficit-/Hyperactivity Disorder (ADHD). Oxygenated hemoglobin in the prefrontal cortex of children with ADHD was measured and fed back. 12 sessions...

Cite
Marx AM, Ehlis AC, Furdea A, et al. Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study. Front Hum Neurosci. 2015;8:1038doi: 10.3389/fnhum.2014.01038.
Marx, A. M., Ehlis, A. C., Furdea, A., Holtmann, M., Banaschewski, T., Brandeis, D., Rothenberger, A., Gevensleben, H., Freitag, C. M., Fuchsenberger, Y., Fallgatter, A. J., & Strehl, U. (2014). Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study. Frontiers in human neuroscience, 81038. https://doi.org/10.3389/fnhum.2014.01038
Marx, Anna-Maria, et al. "Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study." Frontiers in human neuroscience vol. 8 (2014): 1038. doi: https://doi.org/10.3389/fnhum.2014.01038
Marx AM, Ehlis AC, Furdea A, Holtmann M, Banaschewski T, Brandeis D, Rothenberger A, Gevensleben H, Freitag CM, Fuchsenberger Y, Fallgatter AJ, Strehl U. Near-infrared spectroscopy (NIRS) neurofeedback as a treatment for children with attention deficit hyperactivity disorder (ADHD)-a pilot study. Front Hum Neurosci. 2015 Jan 07;8:1038. doi: 10.3389/fnhum.2014.01038. eCollection 2014. PMID: 25610390; PMCID: PMC4285751.
Copy Download .nbib Format: NLM
Detailed analysis of adenosine A2a receptor (.

Oncoimmunology

Vogt TJ, Gevensleben H, Dietrich J, Kristiansen G, Bootz F, Landsberg J, Goltz D, Dietrich D.
PMID: 30221045
Oncoimmunology. 2018 Apr 18;7(8):e1452579. doi: 10.1080/2162402X.2018.1452579. eCollection 2018.

No abstract available.

Cite
Vogt TJ, Gevensleben H, Dietrich J, et al. Detailed analysis of adenosine A2a receptor (. Oncoimmunology. 2018;7(8):e1452579doi: 10.1080/2162402X.2018.1452579.
Vogt, T. J., Gevensleben, H., Dietrich, J., Kristiansen, G., Bootz, F., Landsberg, J., Goltz, D., & Dietrich, D. (2018). Detailed analysis of adenosine A2a receptor (. Oncoimmunology, 7(8), e1452579. https://doi.org/10.1080/2162402X.2018.1452579
Vogt, Timo J, et al. "Detailed analysis of adenosine A2a receptor (." Oncoimmunology vol. 7,8 (2018): e1452579. doi: https://doi.org/10.1080/2162402X.2018.1452579
Vogt TJ, Gevensleben H, Dietrich J, Kristiansen G, Bootz F, Landsberg J, Goltz D, Dietrich D. Detailed analysis of adenosine A2a receptor (. Oncoimmunology. 2018 Apr 18;7(8):e1452579. doi: 10.1080/2162402X.2018.1452579. eCollection 2018. PMID: 30221045; PMCID: PMC6136855.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries